Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Pediatric pericarditis presents challenges in its management, necessitating effective therapeutic interventions. Colchicine, known for its efficacy in adults, requires further investigation for its application and safety in pediatric cohorts. A systematic search across renowned databases identified relevant literature on colchicine use in pediatric pericarditis. Twenty-nine articles underwent rigorous screening, with 18 studies meeting inclusion criteria. Data extraction, quality assessment, and synthesis were conducted meticulously. Included studies comprised case reports, case series, and retrospective cohort studies. Colchicine demonstrated efficacy in reducing recurrence rates and symptom burden, with doses ranging from 0.25 mg/day to 2 mg/day. Adverse events were minimal, predominantly gastrointestinal. Notably, nausea was the most common side effect reported. The safety profile of colchicine was favorable, with rare instances of hepatic and hematologic toxicity. Colchicine emerges as a promising therapeutic option for pediatric pericarditis, demonstrating efficacy in reducing recurrence rates and alleviating symptoms. Its favorable safety profile suggests potential as a preferred long-term therapy. However, further research, including randomized controlled trials, is warranted to confirm its efficacy and safety and explore potential combination therapies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00246-024-03606-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Teenage heartache: A 14-year-old with pleuritic chest pain.
Paediatr Child Health
August 2025
Division of Pediatric Rheumatology, British Columbia Children's Hospital, Vancouver, British Columbia, Canada.
Adverse events associated with COVID-19 vaccination or diagnosis among pregnant and non-pregnant women in the United States, 2021-2022.
Int J Infect Dis
September 2025
University of San Francisco, Department of Nursing and Health Professions, San Francisco, California, United States; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia; Department of Epidemiology, Fielding School of Public Health, University of California, Los A
Objectives: To quantify the incidence of adverse events given COVID-19 vaccination and COVID-19 diagnosis in women of reproductive age; to examine pregnancy as a potential risk modifier.
Methods: An exposure-matched cohort study of >1 million women, 11 December 2020-30 September 2022, United States. COVID-19 vaccination, COVID-19 diagnoses, and medically-attended adverse events - including immunologic, neurologic, cerebrovascular, thromboembolic, cardiovascular, respiratory, thrombocytopenic and coagulative events - were identified from inpatient and outpatient medical claims.
A frameshift mutation in the PRG4 gene causing camptodactyly-arthropathy-coxa vara-pericarditis syndrome: a case report.
Mod Rheumatol Case Rep
July 2025
Medical Genetics Diagnosis Laboratory, Near East University Hospital, Nicosia, Cyprus.
Camptodactyly-arthropathy-coxa vara-pericarditis syndrome (CACP) is an example of a rare non-inflammatory familial arthropathy inherited in an autosomal recessive manner. The proteoglycan 4 (PRG4) gene, located on chromosome 1q25-q31, is responsible for encoding a lubricating glycoprotein found in the synovial fluid and on the surface of articular cartilage. Pathogenic mutations in the PRG4 gene have been associated with CACP disease.
View Article and Find Full Text PDFJuvenile idiopathic arthritis or skeletal dysplasia: first case report of camptodactyly-arthropathy-coxa vara-pericarditis from Iran.
BMC Musculoskelet Disord
August 2025
Department of Pediatrics, Mofid Children's Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Camptodactyly-arthropathy-coxa vara-pericarditis (CACP) syndrome is an inherited autosomal recessive disorder resulting from a mutation in the PRG4 gene located on chromosome one. This mutation leads to either a deficiency or dysfunction of a glycoprotein known as lubricin, which plays a crucial role in inhibiting synovial inflammation and lubricating synovial joints and visceral cavities. CACP syndrome is characterized by a tetrad of manifestations, including congenital or early-onset camptodactyly, childhood-onset non-inflammatory arthropathy accompanied by synovial hyperplasia, coxa vara deformity, and non-inflammatory pericardial effusion.
View Article and Find Full Text PDFIL-1 Pathway Inhibition in Recurrent Pericarditis Management: Real-World Adoption of Corticosteroid Sparing in RESONANCE.
JACC Adv
August 2025
Department of Medical Affairs, Kiniksa Pharmaceuticals, Lexington, Massachusetts, USA.
Background: Recurrent pericarditis (RP) guidelines recommend second-line corticosteroids after aspirin/nonsteroidal anti-inflammatory drugs/colchicine, but complications of protracted use underscore the importance of corticosteroid-sparing strategies.
Objectives: Given clinical trial evidence supporting interleukin (IL)-1 pathway inhibition and US Food and Drug Administration approval of rilonacept in RP, the objective was to assess temporal trends in corticosteroid-sparing treatment of RP in a multicenter registry.
Methods: RESONANCE (REgiStry Of the NAtural history of recurreNt periCarditis in pEdiatric and adult patients; NCT04687358) combines retrospective and prospective data from clinical practice into a single observation period.